Our company is involved in several internationally-funded research contracts. Many of our reagents are developed in close collaboration with scientists worldwide. We are involved in numerous projects and therefore constantly offer a cutting-edge range of innovative reagents. If you are seeking a dynamic SME to apply for a grant in the field of drug and gene delivery, please get in touch with us at business@ozbiosciences.com.
AWARDED EUROPEAN GRANTS
sINPAIN
A game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to treat knee osteoarthritis.
REASON
Regenerating the diabetic heart and kidney by using stress-specific thyroid hormone nanocarriers.
SBR
Smart Bone Regeneration - Novel Regeneration Techniques for Large Bone Defects.
cmRNAbone
3D Printed-Matrix Assisted Chemically Modified RNAs Bone Regenerative Therapy for Trauma and Osteoporotic Patients - A novel Gene Therapy for Bone Regeneration.
LIQD-CORNEA
A liquid corneal glue-filler as an alternative to transplantation in high-risk patients. EuroNanoMed III.
MODIFY-NK
A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours. Eurostars.
UNIVAX
A "Universal" Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines. FP-7 (HEALTH-F3-2013-601738).
GAMBA
Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis. FP7 (NMP3-SL-2010-245993).
CLINIGENE
European Network for the advancement of Clinical Gene Transfer & Therapy. FP6 (LSHB-CT-2006-018933).
EPICURE
Functional genomics and neurobiology of epilepsy: a basis for new therapeutic strategies. FP6 (LSHM-CT-2006-037315).
MAGSELECTOFECTION
Combined isolation and stable non-viral transfection of hematopoietic cells – a novel platform technology for ex vivo hematopoietic stem cell gene therapy. FP6 (LSHB-CT-2006-019038).
IMPROVED PRECISION
Improved precision of nucleic acid based therapy of cystic fibrosis. FP6 (LSHB-CT-2004-005213).
Marie Skłodowska-Curie Actions - MSCA
OcuTher
Educational Network in Ocular Drug Delivery and Therapeutics - This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722717.
NANOMED
“Nanomedicine: an integrative approach”. MARIE SKŁODOWSKA-CURIE ACTIONS HEALTH, H2020-MSCA-ITN-2015.
Partners
CIR AGREEMENT
|
Oz Biosciences has obtained the Crédit d’Impôt Recherche (CIR) Agreement by the French Ministry of Higher Education, Research, and Innovation. This official accreditation enables French companies looking to collaborate with us on a biology R&D project (drug delivery, mRNAs, LNPs,...) to benefit from this accreditation and receive tax advantages. Contact us to explore how we can collaborate on your next R&D project! |
|
